2025.

• Apr.28.2025 Corporate

  Revisions of Consolidated Financial Forecasts

• Apr.25.2025 Licensing

  Ono Enters into a Basic Agreement with Seikagaku for Co-development and Marketing Collaboration on Gel-One for the treatment of Osteoarthritis in Japan

• Apr.24.2025 R & D

  Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting

• Apr.21.2025 Licensing

  Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics

• Apr.18.2025 Sustainability

  ONO Achieves Top 1% in S&P Sustainability Yearbook 2025

• Apr.14.2025 R & D

  U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

• Apr.11.2025 R & D

  U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer

• Apr.07.2025 Corporate

  Announcement on Changes of the Board of Directors and Corporate Officers

• Mar.31.2025 Licensing

  Ono Enters into Drug Discovery Collaboration Agreement with Reborna Biosciences to Generate RNA-Targeting Novel Small Molecule in the Central Nervous System Area

• Mar.31.2025 R & D

  Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

• Mar.31.2025 R & D

  Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1 Expression ≥1%

• Mar.12.2025 Licensing

  Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera

• Mar.10.2025 R & D

  Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

• Feb.28.2025 Corporate

  Ono Pharmaceutical Announces Reorganization of its US and Europe Operations

• Feb.25.2025 R & D

  U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer

• Feb.17.2025 R & D

  U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

• Feb.04.2025 R & D

  Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial

• Feb.03.2025 Management / Finance

  Announcement on Financial Results for FY2024 Q3

• Feb.03.2025 R & D

  Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

• Jan.27.2025 R & D

  Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer

• Jan.06.2025 R & D

  U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications